Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)

Antonio Cascio, Barbara Menzaghi, Barbara Menzaghi, Chiara Dentone, Migliorino, Martini, Maria Gussio, Nunnari, Andrea Gori, Motta, Andrea Parisini, Fabio Conti, Laura Ambra Nicolini, Trizzino, Lucia Taramasso, Lucia Taramasso, Giovanni F. Pellicanò, Giordano Madeddu, Paolo Bonfanti, GuastavignaSalomoni, Giuliana Guadagnino, Paolo Maggi, Madeddu, Parruti, Antonio Di Biagio, Orofino, Gori, Bonfanti, Parruti, Antonio Di Biagio, Di Biagio, Falasca, Puoti, Massimo Puoti, Bandera, Rusconi, Martinelli, Cordier, Giuseppe Vittorio De Socio, De Socio, Goffredo Angioni, Angioni, Squillace, Pellicanò, Mameli, Farinazzo, Leonardo Calza, Sarchi, Goffredo Angioni, Pellicanò, Madeddu, Conti, Chichino, Martini, Dentone, Cibelli, Antonio Di Biagio, Calza, Di Biagio, Bonfanti, Maggi, Di Biagio, De Socio, Paolo Bonfanti, Falasca, Giovanni Cenderello, Roberto Gulminetti, Celesia, Giuseppe Vittorio De Socio, Laura Valsecchi, Laura Valsecchi, Molteni, Rizzardini, Massimo Puoti, Mastroianni, Francesca Vichi, Stefano Rusconi, Cascio, Paolo Maggi, Paolo Maggi, Gioacchino Angarano, Leonardo Calza, Calza, Elena Ricci, Nicola Squillace, Bellacosa, Donatella C. Cibelli, Marcello Trizzino

Research output: Contribution to journalArticle

Abstract

Background: Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods: Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking of not normally distributed variables. Results: A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholesterolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 130 or statin use) was present in 121 (48.6%) and hypertriglyceridemia, (triglycerides (TG) ≥ 200 mg/dl or fibrate use) in 41 (16.5%) patients. Blood lipid profile did not change significantly in either the global population or patients with HC. After a median observation of 17 months (IQR 13-20), 59 (25.3%) patients discontinued DRV/c, of which 13 were in DT. The durability DT resulted higher than that of triple therapy (log-rank test p = 0.01). Main reasons for stopping DRV/c were simplification (15 patients), adverse events (13 patients), planned discontinuation for treatment initiation with DAA (4 patients), treatment failure (2 patients); death (2 patients), other causes (10 patients). Twenty-six were lost to follow-up. Conclusions: DRV/c was safe and well tolerated. Dual therapies showed a better profile of tolerability and a longer durability compared to triple therapies.
Original languageEnglish
Pages (from-to)21-
Number of pages8
JournalAIDS Research and Therapy
Volume16
Publication statusPublished - 2019

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Virology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)'. Together they form a unique fingerprint.

  • Cite this

    Cascio, A., Menzaghi, B., Menzaghi, B., Dentone, C., Migliorino, Martini, Gussio, M., Nunnari, Gori, A., Motta, Parisini, A., Conti, F., Nicolini, L. A., Trizzino, Taramasso, L., Taramasso, L., Pellicanò, G. F., Madeddu, G., Bonfanti, P., ... Trizzino, M. (2019). Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA). AIDS Research and Therapy, 16, 21-.